Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS)--a systematic enquiry and overview

Rajesh Varma, Deepali Sinha, Sinha D, Gupta JK, Janesh Gupta, Janesh K Gupta
European journal of obstetrics, gynecology, and reproductive biology · 2005 · vol. 125(1) , pp. 9–28 · doi:10.1016/j.ejogrb.2005.10.029 · PMID:16325993 · W2154350404
Review OA: closed CC0 ⤵ 33 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This systematic review explores the non-contraceptive applications of the levonorgestrel-releasing intrauterine system (LNG-IUS), analyzing its effectiveness and safety for various gynecological conditions.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Levonorgestrel releasing-intrauterine systems (LNG-IUS) were originally developed as a method of contraception in the mid 1970s. The only LNG-IUS approved for general public use is the Mirena LNG-IUS, which releases 20 mcg of levonorgestrel per day directly in to the uterine cavity. However, new lower dose (10 and 14 mcg per day) and smaller sized LNG-IUS (MLS, FibroPlant-LNG) are currently under clinical development and investigation. Research into the non-contraceptive uses of LNG-IUS is rapidly expanding. In the UK, LNG-IUS is licensed for use in menorrhagia and to provide endometrial protection to perimenopausal and postmenopausal women on estrogen replacement therapy. There is limited evidence to suggest that LNG-IUS may also be beneficial in women with endometriosis, adenomyosis, fibroids, endometrial hyperplasia and early stage endometrial cancer (where the patient is deemed unfit for primary surgical therapy). This systematic enquiry and overview evaluates the quality of evidence relating to the non-contraceptive therapeutic uses of LNG-IUS in gynaecology.

My notes (saved in your browser only)

Condition tags

dysmenorrheaendometriosis

MeSH descriptors

Levonorgestrel Delayed-Action Preparations Delayed-Action Preparations Delayed-Action Preparations Dysmenorrhea Dysmenorrhea Dysmenorrhea Endometrial Hyperplasia Endometrial Hyperplasia Endometrial Hyperplasia Endometrial Neoplasms Endometrial Neoplasms Endometrial Neoplasms Endometriosis Endometriosis Endometriosis Estrogen Replacement Therapy Estrogen Replacement Therapy Estrogen Replacement Therapy Estrogen Replacement Therapy

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (100)

Cited by (32)

Source provenance

europepmc
last seen: 2026-10-15T06:08:49.021275+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:03:30.943773+00:00
License: CC0 · commercial use OK